Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review

被引：18

作者：

Prieto-Pena, Diana ^{[4
]}

Bernabeu, Pilar ^{[5
]}

Vela, Paloma ^{[5
]}

Narvaez, Javier ^{[6
]}

Fernandez-Lopez, Jesus C. ^{[7
]}

Freire-Gonzalez, Mercedes ^{[7
]}

Gonzalez-Alvarez, Beatriz ^{[8
]}

Solans-Laque, Roser ^{[9
]}

Callejas Rubio, Jose L. ^{[10
]}

Ortego, Norberto ^{[10
]}

Fernandez-Diaz, Carlos ^{[11
]}

Rubio, Esteban ^{[12
]}

Garcia-Morillo, Salvador ^{[12
]}

Minguez, Mauricio ^{[13
]}

Fernandez-Carballido, Cristina ^{[13
]}

de Miguel, Eugenio ^{[14
]}

Melchor, Sheila ^{[15
]}

Salgado, Eva ^{[16
]}

Bravo, Beatriz ^{[17
]}

Romero-Yuste, Susana ^{[18
]}

Salvatierra, Juan ^{[10
]}

Hidalgo, Cristina ^{[19
]}

Manrique, Sara ^{[20
]}

Romero-Gomez, Carlos ^{[20
]}

Moya, Patricia ^{[21
]}

Alvarez-Rivas, Noelia ^{[22
]}

Mendizabal, Javier ^{[23
]}

Ortiz-Sanjuan, Francisco ^{[24
]}

Perez de Pedro, Ivan ^{[25
]}

Alonso-Valdivielso, Jose L. ^{[26
]}

Perez-Sanchez, Laura ^{[27
]}

Roldan, Rosa ^{[27
]}

Fernandez-Llanio, Nagore ^{[28
]}

Gomez de la Torre, Ricardo ^{[29
]}

Suarez, Silvia ^{[29
]}

Montesa Cabrera, Maria Jesus ^{[8
]}

Delgado Sanchez, Monica ^{[8
]}

Loricera, Javier ^{[4
]}

Atienza-Mateo, Belen ^{[4
]}

Castaneda, Santos ^{[11
,30
]}

Gonzalez-Gay, Miguel A. ^{[1
,2
,3
]}

Blanco, Ricardo ^{[4
]}

机构：

[1] Hosp Univ Marques de Valdecilla, Rheumatol Div, Res Grp Genet Epidemiol & Atherosclerosis Syst Di, IDIVAL, Ave Valdecilla S-N, Santander 39008, Spain

[2] Univ Cantabria, Sch Med, Santander, Spain

[3] Univ Witwatersrand, Fac Hlth Sci, Sch Physiol, Cardiovasc Pathophysiol & Genom Res Unit, Johannesburg, South Africa

[4] Hosp Univ Marques de Valdecilla, Dept Rheumatol, IDIVAL, Res Grp Genet Epidemiol & Atherosclerosis Syst Di, Santander, Spain

[5] Hosp Gen Alicante, Dept Rheumatol, Alicante, Spain

[6] Hosp Bellvitge Princeps Espanya, Dept Rheumatol, Barcelona, Spain

[7] Complejo Hosp Univ A Coruna, Dept Rheumatol, La Coruna, Spain

[8] Hosp Nuestra Senora Candelaria, Dept Rheumatol, Tenerife, Spain

[9] Hosp Valle De Hebron, Dept Internal Med, Barcelona, Spain

[10] Hosp San Cecilio, Autoimmune Dis Unit, Granada, Spain

[11] Hosp Univ Princesa, Dept Rheumatol, IIS Princesa, Madrid, Spain

[12] Hosp Virgen Rocio, Autoimmune Dis Unit, Seville, Spain

[13] Hosp San Juan Alicante, Dept Rheumatol, Alicante, Spain

[14] Hosp Univ La Paz, Dept Rheumatol, Madrid, Spain

[15] Hosp Univ 12 Octubre, Dept Rheumatol, Madrid, Spain

[16] Complejo Hosp Univ Ourense, Dept Rheumatol, Orense, Spain

[17] Hosp Virgen Nieves, Dept Rheumatol, Granada, Spain

[18] Complejo Hosp Univ Pontevedra, Dept Rheumatol, Pontevedra, Spain

[19] Complejo Univ Salamanca, Dept Rheumatol, Salamanca, Spain

[20] Hosp Reg Malaga, Autoimmune Dis Unit, Malaga, Spain

[21] Hosp Santa Creu & Sant Pau, Dept Rheumatol, Barcelona, Spain

[22] Hosp Univ San Agustin, Dept Rheumatol, Aviles, Spain

[23] Complejo Hosp Navarra, Dept Rheumatol, Pamplona, Spain

[24] Hosp Univ & Politecn La Fe, Dept Rheumatol, Valencia, Spain

[25] Hosp Carlos Haya, Autoimmune Dis Unit, Malaga, Spain

[26] Hosp Univ Burgos, Dept Rheumatol, Burgos, Spain

[27] Hosp Univ Reina Sofia, Dept Rheumatol, Cordoba, Spain

[28] Hosp Arnau Vilanova, Dept Rheumatol, Valencia, Spain

[29] Hosp Univ Cent Asturias, Autoimmune Dis Unit, Oviedo, Spain

[30] Univ Autonoma Madrid IUAMI, UAM ROCHE, EPID Future, Madrid, Spain

来源：

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE | 2021年 / 13卷

关键词：

biological therapy; Caucasian; cDMARDs; Takayasu's arteritis; Tocilizumab; DISEASE-ACTIVITY; EPIDEMIOLOGY; EFFICACY; FEATURES; CRITERIA; OUTCOMES; SAFETY; JAPAN;

D O I：

10.1177/1759720X211020917

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZ(MONO)) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZ(COMBO)) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5-50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0-31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5-50.0) to 5.0 (0.0-5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0-14.0) months. Twenty-three (42.6%) patients were on TCZ(MONO) and 31 (57.4%) on TCZ(COMBO): MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZ(COMBO) were younger [38.0 (27.0-46.0) versus 45.0 (38.0-57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0-38.0) versus 6.0 (1.0-23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7-5.6) versus 1.3 (0.3-3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.

引用

页数：12

共 50 条

[41] EFFICACY AND SAFETY OF TNF-A ANTAGONISTS AND TOCILIZUMAB IN TAKAYASU ARTERITIS: MULTICENTER WORLDWIDE RETROSPECTIVE STUDY OF 209 PATIENTS
Mekinian, A.
Biard, L.
Dagna, L.
Jego, P.
Salvarani, C.
Sergey, M.
Espitia, O.
Sciascia, S.
Hernan, P.
Cacoub, P.
Fain, O.
Saadoun, D.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 37 - 37
[42] Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis
Arita, Yoh
Nakaoka, Yoshikazu
Otsuki, Michio
Higuchi, Kaori
Hashimoto-Kataoka, Takahiro
Yasui, Taku
Masaki, Takeshi
Ohtani, Tomohito
Kishimoto, Tadamitsu
Yamauchi-Takihara, Keiko
Komuro, Issei
Sakata, Yasushi
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 187 : 319 - 321
[43] Tocilizumab for faster and safer remission of Takayasu's arteritis
Liao, Hua
Du, Juan
Li, Taotao
Pan, Lili
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2022, 13
[44] The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis
Zhou, J.
Chen, Z.
Li, J.
Yang, Y.
Zhao, J.
Chen, H.
Liu, M.
Sun, F.
Li, M.
Tian, X.
Zeng, X.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (01) : S171 - S175
[45] Successful Remission Induction of MTX and anti-TNF-α-refractory Takayasu's Arteritis with Tocilizumab
Zaenker, M.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 147 - 147
[46] EFFICACY AND SAFETY OF TOCILIZUMAB IN EIGHT PATIENTS WITH TAKAYASU ARTERITIS
Palmou-Fontana, N.
Loricera, J.
Blanco, R.
Hernandez, J. L.
Castaneda, S.
Humbria, A.
Ortego, N.
Bravo, B.
Freire, M.
Melchor, S.
Minguez, M.
Salvatierra, J.
Gonzalez-Vela, C.
Calvo-Rio, V.
Pina, T.
Gonzalez-Gay, M. A.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 301 - 301
[47] Treatment of Refractory Takayasu Arteritis with Tocilizumab: 7 Italian Patients from a Single Referral Center
Tombetti, Enrico
Franchini, Stefano
Papa, Maurizio
Sabbadini, Maria Grazia
Baldissera, Elena
JOURNAL OF RHEUMATOLOGY, 2013, 40 (12) : 2047 - 2051
[48] Refractory Takayasu arteritis in a 65-year-old Caucasian woman
Gruber, R.
Weber, F.
Sepp, N.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (02) : 191 - 193
[49] Pediatric Takayasu Arteritis: A Review of the Literature
Haslak, Fatih
Yildiz, Mehmet
Sahin, Sezgin
Adrovic, Amra
Barut, Kenan
Kasapcopur, Ozgur
CURRENT PEDIATRIC REVIEWS, 2022, 18 (04) : 243 - 250
[50] ANTI-INTERLEUKIN-6 (TOCILIZUMAB) EXPERIENCE IN TAKAYASU'S ARTERITIS PATIENTS
Kilic, L.
Karadag, O.
Erden, A.
Sari, A.
Armagan, B.
Firat, E.
Kalyoncu, U.
Bilgen, S. Apras
Kiraz, S.
Ertenli, I.
Akdogan, A.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 437 - 438

← 1 2 3 4 5 →